Stereotaxis, Inc. (STXS)
| Market Cap | 348.53M |
| Revenue (ttm) | 26.70M |
| Net Income (ttm) | -7.94M |
| Shares Out | 74.49M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $4.36 |
| Previous Close | $4.74 |
| Change ($) | -0.38 |
| Change (%) | -8.02% |
| Day's Open | 4.65 |
| Day's Range | 4.36 - 4.69 |
| Day's Volume | 144,216 |
| 52-Week Range | 1.77 - 5.47 |
Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2020 Results - Earnings Call Transcript
Stereotaxis, Inc.'s (STXS) CEO David Fischel on Q3 2020 Results - Earnings Call Transcript
ST. LOUIS, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial r...
ST. LOUIS, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it wi...
ST. LOUIS, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it ha...
ST. LOUIS, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that ...
ST. LOUIS, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that D...
ST. LOUIS, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a pion...
Stereotaxis, Inc. (STXS) CEO David Fischel on Q2 2020 Results - Earnings Call Transcript
ST. LOUIS, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financi...
ST. LOUIS and CARLSBAD, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Acutus Medical today announced the first integrated cardiac ablation procedure benefiting f...
ST. LOUIS, July 23, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that i...
ST. LOUIS, July 13, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publ...
ST. LOUIS, June 22, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that t...
Robotics stocks offer multi-decade growth potential. These 10 stocks offer some of the best exposure to this attractive trend.
ST. LOUIS, June 18, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that D...
ST. LOUIS, June 02, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has...
ST. LOUIS, May 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it h...
Stereotaxis, Inc. (STXS) CEO David Fischel on Q1 2020 Results - Earnings Call Transcript
Stereotaxis, Inc. (STXS) CEO David Fischel on Q4 2019 Results - Earnings Call Transcript
ST. LOUIS, March 06, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today it has ...
Stereotaxis: A Small But Stellar Performer In The Medical Robotics Space
ST. LOUIS, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that H...
A series of financial missteps led to a delisting for Stereotaxis in 2013. Now that a new CEO has made some progress toward a turnaround, the robotic technology company may deserve a second ch...
Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2019 Results - Earnings Call Transcript
ST. LOUIS and MT. OLIVE, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treate...
ST. LOUIS and PESSAC, France, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and inHEART today announced the first patients have been successfully treated with the i...
ST. LOUIS and BARCELONA, Spain, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and ADAS 3D Medical SL today announced the first patients have been successfully treat...
Accuray and Stereotaxis are hyper-focused on growth.
ST. LOUIS, Mo., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today a...
About STXS
Stereotaxis designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system that offers navig... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Aug 12, 2004 |
| CEO David Fischel | Employees 118 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol STXS |
Analyst Forecasts
According to 3 analysts, the average rating for Stereotaxis stock is "Strong Buy." The 12-month stock price forecast is 7.33, which is an increase of 68.12% from the latest price.